Very Early Surfactant and NCPAP for Premature Infants With RDS - Full Text View

Purpose

The present study will test the use of very early nasal continuous airway pressure(NCPAP)with and without surfactant in premature infants with clinical evidence or respiratory distress syndrome. We hypothesize that premature infants exposed to very early NCPAP and surfactant will require less mechanical ventilation compared to those premature infants exposed to NCPAP alone.

Condition	Intervention	Phase
Respiratory Distress Syndrome Pneumothorax/Pulmonary Intersticial Emphysema Chronic Lung Disease	Other: Very early surfactant and bubble NCPAP Other: bubble NCPAP	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Very Early Surfactant Without Mandatory Ventilation In Premature Infants Treated With Early Continuous Positive Airway Pressure-A Randomized Controlled Trial

Resource links provided by NLM:

Genetics Home Reference related topics: primary spontaneous pneumothorax

Genetic and Rare Diseases Information Center resources: Respiratory Distress Syndrome, Infant Acute Respiratory Distress Syndrome

U.S. FDA Resources

Further study details as provided by Colombian Neonatal Research Network:

Primary Outcome Measures:

Need for mechanical ventilation [ Time Frame: Death or discharge from the NICU ]

Secondary Outcome Measures:

Neonatal mortality [ Time Frame: During hospitalization in the NICU ]
Air leak syndrome [ Time Frame: death or discharge from the NICU ]
Oxygen dependency at 36 weeks post menstrual age [ Time Frame: Death or discharge from the NICU ]


Enrollment:	278
Study Start Date:	January 2004
Study Completion Date:	December 2006

Arms	Assigned Interventions
Experimental: 1 Early NCPAP plus very early surfactant	Other: Very early surfactant and bubble NCPAP For patients randomized to early NCPAP plus surfactant, 4ml/kg of surfactant were administered through an endotracheal tube in two aliquots, 2 minutes apart followed by positive pressure ventilation administered for one minute with a Neopuff Infant Resuscitator pre-set to give a peak pressure of 20 cm H2O and 5 cm H2O of positive end expiratory pressure. Infant was then extubated and placed on NCPAP of 6 cmH2O
Active Comparator: 2 NCPAP alone	Other: bubble NCPAP Premature infants randomized to bubble NCPAP alone will continue on NCPAP until they reach "yes or no" treatment failure criteria.

Arms

Assigned Interventions

Experimental: 1

Early NCPAP plus very early surfactant

Other: Very early surfactant and bubble NCPAP

For patients randomized to early NCPAP plus surfactant, 4ml/kg of surfactant were administered through an endotracheal tube in two aliquots, 2 minutes apart followed by positive pressure ventilation administered for one minute with a Neopuff Infant Resuscitator pre-set to give a peak pressure of 20 cm H2O and 5 cm H2O of positive end expiratory pressure. Infant was then extubated and placed on NCPAP of 6 cmH2O

Active Comparator: 2

NCPAP alone

Other: bubble NCPAP

Premature infants randomized to bubble NCPAP alone will continue on NCPAP until they reach "yes or no" treatment failure criteria.

Detailed Description:

Premature infants who are not intubated during the first 15 minutes of life and who develop clinical evidence of respiratory distress or need for oxygen requirement between 15 and 60 minutes of life, will be placed on bubble NCPAP of 6 cm H2O. Randomization envelops will them be opened and patients will be assigned to continuation on NCPAP alone (Control Group) or to NCPAP plus very early surfactant therapy (Treatment Group). Patients assigned to the treatment group will be transiently intubated for surfactant administration, extubated, and placed back on NCPAP of 6 cm H2O. Both groups will then be followed over time to determine which infants meet treatment failure criteria defined as: Treatment failure was defined a priori by either failure of adequate oxygenation or ventilation as follows: "1" FiO2 greater than 0.75 for more than 30 minutes to maintain SpO2 within the pre-established target ranges, "2" persistent or recurrent desaturation below 80% that did not respond to suctioning of the airways and PPV, "3" PCO2>65 mmHg and pH<7.22 on an arterial or capillary blood gas analysis, in association with increased work of breathing. Infants in the Treatment Group who cannot be extubated after their initial dose of surfactant because of clinical instability will be analyzed as treatment failures. Premature infants that meet treatment failure criteria on either arm will be intubated and placed on mechanical ventilation and given surfactant rescue doses according to the criteria of the participating institutions. Premature infants with respiratory distress syndrome who do not meet treatment failure criteria in both groups will remain on NCPAP until their respiratory failure improves.

Eligibility


Ages Eligible for Study:	27 Weeks to 31 Weeks (Child)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Gestational age of 27 to 31 6/7 weeks,
Postnatal age between 15 and 60 minutes,
Supplemental oxygen requirement or evidence of increased work of breathing (tachypnea, intercostal retractions, nasal flaring, or grunting), and
Prenatal consent.

Exclusion Criteria:

Apgar score less than 2 at 5 minutes,
Intubation prior to randomization,
Prenatal diagnosis of major congenital anomalies,
Prolonged rupture of membranes of greater than 3 weeks duration, and
Infants who were likely to be transferred to another center soon after birth were not enrolled in the study.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00563641

Locations


Colombia
Department of Epidemiology and Biostatistics Pontificia Universidad Javeriana
Bogota, Cundinamarca, Colombia

Sponsors and Collaborators

Colombian Neonatal Research Network

Pontificia Universidad Javeriana

Vanderbilt University School of Medicine

Abbott

Fisher and Paykel Healthcare

Investigators


Principal Investigator:	Mario A Rojas, MD, MPH	Vanderbilt University

More Information

Additional Information:

website for Pontificia Universidad Javeriana Research This link exits the ClinicalTrials.gov site

Publications:

Rojas MA, Lozano JM, Rojas MX; Colombian Neonatal Research Network. International collaborative research: a Colombian model that promotes infant health and research capacity. J Perinatol. 2007 Dec;27(12):738-43. Epub 2007 Sep 20. Review. Erratum in: J Perinatol. 2007 Dec;27(12):808.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Rojas MA, Lozano JM, Rojas MX, Laughon M, Bose CL, Rondon MA, Charry L, Bastidas JA, Perez LA, Rojas C, Ovalle O, Celis LA, Garcia-Harker J, Jaramillo ML; Colombian Neonatal Research Network. Very early surfactant without mandatory ventilation in premature infants treated with early continuous positive airway pressure: a randomized, controlled trial. Pediatrics. 2009 Jan;123(1):137-42. doi: 10.1542/peds.2007-3501.


ClinicalTrials.gov Identifier:	NCT00563641 History of Changes
Other Study ID Numbers:	ColombianCNRNCPAP trial Abbott Laboratories Grant
Study First Received:	November 23, 2007
Last Updated:	November 23, 2007
Health Authority:	Colombia:Research Promotion Office. Academic Vice Rectory Pontificia Universidad Javeriana.

Keywords provided by Colombian Neonatal Research Network:


NCPAP Very early surfactant

Additional relevant MeSH terms:


Lung Diseases Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Emphysema Pneumothorax Respiratory Tract Diseases Respiration Disorders	Infant, Premature, Diseases Infant, Newborn, Diseases Pathologic Processes Pleural Diseases Pulmonary Surfactants Respiratory System Agents

ClinicalTrials.gov processed this record on September 30, 2016

Very Early Surfactant and NCPAP for Premature Infants With RDS (CNRNCPAP)